Ask about this productRelated genes to: Plxdc2 Blocking Peptide
- Gene:
- PLXDC2 NIH gene
- Name:
- plexin domain containing 2
- Previous symbol:
- -
- Synonyms:
- TEM7R, FLJ14623
- Chromosome:
- 10p12.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-08-27
- Date modifiied:
- 2016-10-05
Related products to: Plxdc2 Blocking Peptide
Related articles to: Plxdc2 Blocking Peptide
- Parkinson's disease (PD) is driven by neurodegeneration, iron accumulation, and microglial senescence, yet effective therapy is hindered by the blood-brain barrier (BBB). By constructing the largest-to-date single-cell atlas of the human substantia nigra, we identified a marked upregulation of PLXDC2 in PD microglia. Leveraging this finding, we developed a multifunctional biomimetic nanoplatform (HFn-GM@siPLXDC2/DFO/CeO-NP). This system co-encapsulates the iron chelator deferoxamine and antioxidant CeO nanoparticles, carries PLXDC2-targeting siRNA, and features a ferritin-modified microglial membrane coating to enhance BBB penetration and lesion targeting. In vivo, the nanoplatform efficiently traversed the BBB, reducing iron deposition and reactive oxygen species while suppressing microglial inflammation. Crucially, the treatment significantly alleviated dopaminergic neurodegeneration and improved motor performance-including coordination, balance, and endurance in PD mice. Mechanistically, we demonstrate that PLXDC2 contributes to microglial senescence via the cGAS-STING pathway, and its silencing attenuates neuroinflammation and oxidative stress. This study establishes a potent nanotherapeutic strategy integrating microenvironment remodeling with precise gene regulation to mitigate PD progression and alleviate motor deficits. - Source: PubMed
Publication date: 2026/09/27
Lu HeyueZheng ZitianWang FeiranLuo HuanhuanJu FeiZhu YuchengZhou ZhengSun JieQiu ZhenghuiLuo XiangJia ZhongzhengWang JianquanHuang HongjieZhang Bo - Despite the identification of numerous genetic risk variants for Alzheimer's disease (AD), mechanisms through which these variants act remain unclear. Identifying specific proteins levels affected by genetic variation can provide valuable insights into the underlying biological pathways implicated in AD. - Source: PubMed
Publication date: 2026/09/17
Reus Lianne MJiang ChenyangVilor-Tejedor NataliaBoltz ToniYigit AryaGobom JohanVos Stephanie J BBlennow KajZetterberg HenrikMartinez-Lage PabloTainta MikelPopp JuliusTsolaki MagdaVandenberghe RikFrölich LutzFreund-Levi YvonneDobricic ValerijaBraber Anouk denvan Harten Argonde COphoff Roel AHolstege Hennevan der Flier Wiesje Mvan der Lee Sven JTeunissen Charlotte EBertram LarsVisser Pieter JelleTijms Betty M - Ischemic stroke (IS) is a major cause of death and disability, and creatine metabolism (CM) is potentially involved in its development. This study examined IS candidate biomarkers co-expressed with CM-related genes (CMRGs). IS data and CMRGs were sourced from public databases and published research. We identified candidate genes by intersecting genes from weighted co-expression network analysis and differential expression analysis. Candidate biomarkers were selected via machine learning. A diagnostic nomogram was constructed, and functional roles were explored via enrichment and immune infiltration analyses. Candidate biomarker expression was preliminarily validated by reverse transcription quantitative polymerase chain reaction in a small clinical cohort. Intersection analysis of the 336 differentially expressed genes and 3914 module genes yielded 111 candidate genes. Subsequently, F12 and PLXDC2 were identified as candidate biomarkers, and these genes were upregulated in IS samples. The nomogram based on these candidate biomarkers showed promising capacity for differentiating sample types in the training set, warranting further evaluation in independent cohorts. In addition to enrichment in pathways such as oxidative phosphorylation, VEGF-VEGFR2 signaling, and interleukin signaling, F12 and PLXDC2 were also strongly and positively correlated with neutrophils (r > 0.30, P < 0.001). Further screening highlighted cyclosporin A and trichostatin A as drugs that could simultaneously target both candidate biomarkers. This study identified F12 and PLXDC2 as candidate biomarkers co-expressed with CMRGs, offering preliminary insights that warrant further investigation in larger cohorts. - Source: PubMed
Publication date: 2026/09/18
Li JingjunFeng XiaoxuanLiu ChangSong YangLiu XiaofengSun Jiaan - Functional tooth regeneration remains a major challenge in clinical dentistry and depends on the precise odontogenic/osteogenic commitment of resident stem cells. Micro-peptides encoded by long noncoding RNAs represent a novel source of bioactive molecules for regenerative therapy. This study aimed to investigate whether a newly identified 76-amino acid micro-peptide, PLXDC2-OT-peptide, promotes odontogenic/osteogenic differentiation of stem cells from the apical papilla (SCAPs) and to clarify its underlying mechanism. - Source: PubMed
Publication date: 2026/09/10
Dong ShuangshanSun ZiyanShang JiajianLiu HuinaFan Zhipeng - PLXDC2 is a single-pass transmembrane glycoprotein expressed in multiple stem and immune-related cell types. In human induced pluripotent stem cells (hiPSCs), PLXDC2 mRNA and its corresponding protein have been confirmed by transcriptome analysis and mass spectrometry; however, surface detection by flow cytometry using the monoclonal antibody #4G3 cannot be achieved after routine TrypLE dissociation. This failure is attributable to degradation of protease-sensitive epitopes by TrypLE and membrane-associated proteases such as BACE-1 (β-site APP cleaving enzyme 1). To retain these epitopes, we evaluated a protease-free mechanical dissociation procedure in combination with BACE-1 inhibition during both cell dissociation and antibody staining. This approach enabled reproducible flow cytometric detection of PLXDC2 on 201B7 hiPSCs. Western blot analysis of membrane fractions similarly showed increased PLXDC2 signal intensity when samples were processed in the presence of a BACE-1 inhibitor. These results demonstrate a practical method for improving PLXDC2 detection in hiPSCs and provide a general strategy for analyzing cell-surface proteins that are susceptible to proteolytic cleavage. - Source: PubMed
Publication date: 2026/07/31
Sato TomomiSakuma ChiakiHori ChikaShibata TakashiKomatsu YukiNakagawa MasatakaAkuta Teruo